Peptide Comparisons
Side-by-side evidence comparisons to help you understand the differences between similar compounds.
Showing 269 comparisons
5-Amino-1MQ vs Amycretin
Comparison of 5-Amino-1MQ (Low evidence) and Amycretin (Moderate evidence).
5-Amino-1MQ vs AOD-9604: What the Evidence Shows
5-Amino-1MQ has cell and mouse NNMT-inhibition research, while AOD-9604 has human obesity studies. The larger AOD-9604 phase 2b trial did not show statistically significant weight loss versus placebo. These separate records cannot establish which compound works better in people.
5-Amino-1MQ vs Cagrilintide
Comparison of 5-Amino-1MQ (Low evidence) and Cagrilintide (High evidence).
5-Amino-1MQ vs CagriSema
Comparison of 5-Amino-1MQ (Low evidence) and CagriSema (High evidence).
5-Amino-1MQ vs CT-388
Comparison of 5-Amino-1MQ (Low evidence) and CT-388 (Moderate evidence).
5-Amino-1MQ vs Liraglutide
Comparison of 5-Amino-1MQ (Low evidence) and Liraglutide (High evidence).
5-Amino-1MQ vs MariTide
Comparison of 5-Amino-1MQ (Low evidence) and MariTide (Moderate evidence).
5-Amino-1MQ vs Mazdutide
5-Amino-1MQ and mazdutide differ in mechanism, trial maturity, and regulatory status. The cited studies do not establish a head-to-head efficacy ranking.
5-Amino-1MQ vs Orforglipron
Comparison of 5-Amino-1MQ (Low evidence) and Orforglipron (High evidence).
5-Amino-1MQ vs Pemvidutide
Comparison of 5-Amino-1MQ (Low evidence) and Pemvidutide (Moderate evidence).
5-Amino-1MQ vs Retatrutide
Comparison of 5-Amino-1MQ (Low evidence) and Retatrutide (High evidence).
5-Amino-1MQ vs Semaglutide
Comparing an experimental NNMT inhibitor (5-Amino-1MQ) versus FDA-approved GLP-1 agonist semaglutide for weight loss and metabolic health.
5-Amino-1MQ vs SLU-PP-332
Comparison of 5-Amino-1MQ (Low evidence) and SLU-PP-332 (Very Low evidence).
5-Amino-1MQ vs Survodutide
Comparison of 5-Amino-1MQ (Low evidence) and Survodutide (High evidence).
5-Amino-1MQ vs Tirzepatide
Comparison of 5-Amino-1MQ (Low evidence) and Tirzepatide (High evidence).
5-Amino-1MQ vs VK2735
Comparison of 5-Amino-1MQ (Low evidence) and VK2735 (Moderate evidence).
Alixorexton vs Oveporexton
Comparison of Alixorexton (Moderate evidence) and Oveporexton (Moderate evidence).
Amycretin vs AOD-9604
Comparison of Amycretin (Moderate evidence) and AOD-9604 (Low evidence).
Amycretin vs Cagrilintide
Comparison of Amycretin (Moderate evidence) and Cagrilintide (High evidence).
Amycretin vs CagriSema
Comparison of Amycretin (Moderate evidence) and CagriSema (High evidence).
Amycretin vs CT-388
Comparison of Amycretin (Moderate evidence) and CT-388 (Moderate evidence).
Amycretin vs Liraglutide
Comparison of Amycretin (Moderate evidence) and Liraglutide (High evidence).
Amycretin vs MariTide
Comparison of Amycretin (Moderate evidence) and MariTide (Moderate evidence).
Amycretin vs Mazdutide
Amycretin and mazdutide differ in mechanism, trial maturity, and regulatory status. The cited studies do not establish a head-to-head efficacy ranking.
Amycretin vs Orforglipron
Comparison of Amycretin (Moderate evidence) and Orforglipron (High evidence).
Amycretin vs Pemvidutide
Comparison of Amycretin (Moderate evidence) and Pemvidutide (Moderate evidence).
Amycretin vs Retatrutide
Comparison of Amycretin (Moderate evidence) and Retatrutide (High evidence).
Amycretin vs Semaglutide
Comparing Novo Nordisk's unimolecular GLP-1/amylin dual agonist amycretin with single-target semaglutide.
Amycretin vs SLU-PP-332
Comparison of Amycretin (Moderate evidence) and SLU-PP-332 (Very Low evidence).
Amycretin vs Survodutide
Comparison of Amycretin (Moderate evidence) and Survodutide (High evidence).
Amycretin vs Tirzepatide
Comparing Novo Nordisk's next-generation GLP-1/amylin unimolecular agonist amycretin with Eli Lilly's dual GIP/GLP-1 agonist tirzepatide.
Amycretin vs VK2735
Comparison of Amycretin (Moderate evidence) and VK2735 (Moderate evidence).
AOD-9604 vs Cagrilintide
Comparison of AOD-9604 (Low evidence) and Cagrilintide (High evidence).
AOD-9604 vs CagriSema
Comparison of AOD-9604 (Low evidence) and CagriSema (High evidence).
AOD-9604 vs CT-388
Comparison of AOD-9604 (Low evidence) and CT-388 (Moderate evidence).
AOD-9604 vs Liraglutide
Comparison of AOD-9604 (Low evidence) and Liraglutide (High evidence).
AOD-9604 vs MariTide
Comparison of AOD-9604 (Low evidence) and MariTide (Moderate evidence).
AOD-9604 vs Mazdutide
AOD-9604 and mazdutide differ in mechanism, trial maturity, and regulatory status. The cited studies do not establish a head-to-head efficacy ranking.
AOD-9604 vs MK-677
AOD-9604 obesity trials and MK-677 older-adult trials tested different outcomes; neither establishes general weight-loss benefit.
AOD-9604 vs Orforglipron
Comparison of AOD-9604 (Low evidence) and Orforglipron (High evidence).
AOD-9604 vs Pemvidutide
Comparison of AOD-9604 (Low evidence) and Pemvidutide (Moderate evidence).
AOD-9604 vs Retatrutide
Comparison of AOD-9604 (Low evidence) and Retatrutide (High evidence).
AOD-9604 vs Semaglutide
Comparison of failed AOD-9604 trials versus proven semaglutide for weight management.
AOD-9604 vs SLU-PP-332
Comparison of AOD-9604 (Low evidence) and SLU-PP-332 (Very Low evidence).
AOD-9604 vs Survodutide
Comparison of AOD-9604 (Low evidence) and Survodutide (High evidence).
AOD-9604 vs Tirzepatide
Comparison of AOD-9604 (Low evidence) and Tirzepatide (High evidence).
AOD-9604 vs VK2735
Comparison of AOD-9604 (Low evidence) and VK2735 (Moderate evidence).
BPC-157 vs Chonluten
Comparison of BPC-157 (Low evidence) and Chonluten (Low evidence).
BPC-157 vs GHK
Comparing gastric pentadecapeptide BPC-157 with copper-binding tripeptide GHK for tissue repair research.
BPC-157 vs GHK-Cu vs TB-500
Three-way comparison of popular but unapproved recovery peptides: BPC-157, GHK-Cu, and TB-500.
BPC-157 vs LL-37
BPC-157 has small, heterogeneous human reports; native topical LL-37 has three published wound-trial populations with mixed results. Neither has established general tissue-repair benefit.
BPC-157 vs Sigumir
Comparison of BPC-157 (Low evidence) and Sigumir (Low evidence).
BPC-157 vs TB-500
Comparison of two popular but unapproved peptides marketed for tissue repair and recovery.
Bronchogen vs Epithalon
Comparison of recorded dossier grades and source inventories for Bronchogen and Epithalon.
Bronchogen vs Thymalin
Comparison of recorded dossier grades and source inventories for Bronchogen and Thymalin.
Bronchogen vs Vilon
Bronchogen and Vilon research, with distinct evidence and unresolved clinical questions.
Cagrilintide vs CagriSema
Comparison of Cagrilintide (High evidence) and CagriSema (High evidence).
Cagrilintide vs CT-388
Comparison of Cagrilintide (High evidence) and CT-388 (Moderate evidence).
Cagrilintide vs Liraglutide
Comparison of Cagrilintide (High evidence) and Liraglutide (High evidence).
Cagrilintide vs MariTide
Comparison of Cagrilintide (High evidence) and MariTide (Moderate evidence).
Cagrilintide vs Mazdutide
Cagrilintide and mazdutide differ in mechanism, trial maturity, and regulatory status. The cited studies do not establish a head-to-head efficacy ranking.
Cagrilintide vs Orforglipron
Comparison of Cagrilintide (High evidence) and Orforglipron (High evidence).
Cagrilintide vs Pemvidutide
Comparison of Cagrilintide (High evidence) and Pemvidutide (Moderate evidence).
Cagrilintide vs Retatrutide
Comparison of Cagrilintide (High evidence) and Retatrutide (High evidence).
Cagrilintide vs Semaglutide
Comparing Novo Nordisk's long-acting amylin analog cagrilintide with GLP-1 agonist semaglutide - and their combination (CagriSema).
Cagrilintide vs SLU-PP-332
Comparison of Cagrilintide (High evidence) and SLU-PP-332 (Very Low evidence).
Cagrilintide vs Survodutide
Comparison of Cagrilintide (High evidence) and Survodutide (High evidence).
Cagrilintide vs Tirzepatide
Comparing Novo Nordisk's amylin analog cagrilintide with Eli Lilly's dual GIP/GLP-1 agonist tirzepatide.
Cagrilintide vs VK2735
Comparison of Cagrilintide (High evidence) and VK2735 (Moderate evidence).
CagriSema vs CT-388
Comparison of CagriSema (High evidence) and CT-388 (Moderate evidence).
CagriSema vs Liraglutide
Comparison of CagriSema (High evidence) and Liraglutide (High evidence).
CagriSema vs MariTide
Comparison of CagriSema (High evidence) and MariTide (Moderate evidence).
CagriSema vs Mazdutide
CagriSema and mazdutide differ in mechanism, trial maturity, and regulatory status. The cited studies do not establish a head-to-head efficacy ranking.
CagriSema vs Orforglipron
Comparison of CagriSema (High evidence) and Orforglipron (High evidence).
CagriSema vs Pemvidutide
Comparison of CagriSema (High evidence) and Pemvidutide (Moderate evidence).
CagriSema vs Retatrutide
Comparison of CagriSema (High evidence) and Retatrutide (High evidence).
CagriSema vs Semaglutide
Comparison of CagriSema (High evidence) and Semaglutide (High evidence).
CagriSema vs SLU-PP-332
Comparison of CagriSema (High evidence) and SLU-PP-332 (Very Low evidence).
CagriSema vs Survodutide
Comparison of CagriSema (High evidence) and Survodutide (High evidence).
CagriSema vs Tirzepatide
Novo Nordisk's semaglutide plus cagrilintide combination versus Eli Lilly's GIP/GLP-1 dual agonist tirzepatide.
CagriSema vs VK2735
Comparison of CagriSema (High evidence) and VK2735 (Moderate evidence).
Cardiogen vs Epithalon
Comparison of Cardiogen (Low evidence) and Epithalon (Low evidence).
Cardiogen vs Thymalin
Comparison of Cardiogen (Low evidence) and Thymalin (Moderate evidence).
Cardiogen vs Ventfort
Comparison of Cardiogen (Low evidence) and Ventfort (Very Low evidence).
Cardiogen vs Vesugen
Comparison of Cardiogen (Low evidence) and Vesugen (Low evidence).
Cerebrolysin vs P21
Comparison of Cerebrolysin (Moderate evidence) and P21 (Very Low evidence).
Cerebrolysin vs Semax
Comparing porcine brain-derived peptide mixture cerebrolysin with synthetic ACTH fragment semax for cognitive and neuroprotective applications.
Cerluten vs Cortexin
Comparison of Cerluten (Low evidence) and Cortexin (Moderate evidence).
Cerluten vs Pinealon
Comparison of Cerluten (Low evidence) and Pinealon (Low evidence).
Cerluten vs Selank
Comparison of Cerluten (Low evidence) and Selank (Moderate evidence).
Cerluten vs Semax
Comparison of Cerluten (Low evidence) and Semax (Moderate evidence).
Chonluten vs Epithalon
Comparison of Chonluten (Low evidence) and Epithalon (Low evidence).
Chonluten vs Stamakort
Comparison of Chonluten (Low evidence) and Stamakort (Very Low evidence).
Chonluten vs Thymalin
Comparison of Chonluten (Low evidence) and Thymalin (Moderate evidence).
CJC-1295 vs Ipamorelin
Comparing GHRH analog CJC-1295 with GHRP ipamorelin - often used together but different mechanisms.
CJC-1295 vs Sermorelin
Comparison of modified GHRH analog CJC-1295 with the natural-sequence GHRH analog sermorelin - half-life differences, evidence quality, and practical considerations.
CJC-1295 vs Tesamorelin
CJC-1295 has short healthy-volunteer hormone studies; tesamorelin has FDA-reviewed trials for excess abdominal fat in adults with HIV and lipodystrophy.
Cortexin vs Cerebrolysin
Comparing two brain-derived peptide preparations used in Russia and Eastern Europe for neurological conditions.
Cortexin vs Epithalon
Comparison of Cortexin (Moderate evidence) and Epithalon (Low evidence).
Cortexin vs Pinealon
Comparison of Cortexin (Moderate evidence) and Pinealon (Low evidence).
Cortexin vs Retinalamin
Comparison of Cortexin (Moderate evidence) and Retinalamin (Moderate evidence).
Cortexin vs Selank
Comparison of Cortexin (Moderate evidence) and Selank (Moderate evidence).
Cortexin vs Semax
Comparing two Russian neuropeptide approaches: cortexin (brain tissue extract complex) versus semax (defined synthetic ACTH fragment).
CT-388 vs Liraglutide
Comparison of CT-388 (Moderate evidence) and Liraglutide (High evidence).
CT-388 vs MariTide
Comparison of CT-388 (Moderate evidence) and MariTide (Moderate evidence).
CT-388 vs Mazdutide
CT-388 and mazdutide differ in mechanism, trial maturity, and regulatory status. The cited studies do not establish a head-to-head efficacy ranking.
CT-388 vs Orforglipron
Comparison of CT-388 (Moderate evidence) and Orforglipron (High evidence).
CT-388 vs Pemvidutide
Comparison of CT-388 (Moderate evidence) and Pemvidutide (Moderate evidence).
CT-388 vs Retatrutide
Comparison of CT-388 (Moderate evidence) and Retatrutide (High evidence).
CT-388 vs Semaglutide
Comparison of CT-388 (Moderate evidence) and Semaglutide (High evidence).
CT-388 vs SLU-PP-332
Comparison of CT-388 (Moderate evidence) and SLU-PP-332 (Very Low evidence).
CT-388 vs Survodutide
Comparison of CT-388 (Moderate evidence) and Survodutide (High evidence).
CT-388 vs Tirzepatide
Comparison of CT-388 (Moderate evidence) and Tirzepatide (High evidence).
CT-388 vs VK2735
Comparison of CT-388 (Moderate evidence) and VK2735 (Moderate evidence).
Dihexa vs Cerebrolysin
Comparing synthetic peptide Dihexa with brain-derived peptide mixture Cerebrolysin for cognitive research.
Dihexa vs P21
Comparison of Dihexa (Very Low evidence) and P21 (Very Low evidence).
Dihexa vs Selank
Comparison of Dihexa (Very Low evidence) and Selank (Moderate evidence).
Dihexa vs Semax
Comparing Dihexa (HGF/c-Met pathway) with Semax (ACTH analog) - two different approaches to cognitive enhancement research.
DSIP vs Selank: What Was Studied?
DSIP has small, conflicting human studies of intravenous treatment for insomnia. Selank has a small comparative human study in anxiety-related conditions. Their evidence addresses different questions and does not establish that either is a substitute for the other.
DSIP vs Semax: What Was Studied?
DSIP has small, conflicting human insomnia studies. Semax has human studies in ischemic-stroke care and rehabilitation, plus separate animal mechanism work. Those different settings do not support a head-to-head effectiveness ranking or a claim that the peptides work safely together.
Endoluten vs Epithalon
Comparison of Endoluten (Low evidence) and Epithalon (Low evidence).
Endoluten vs Pinealon
Comparison of Endoluten (Low evidence) and Pinealon (Low evidence).
Endoluten vs Thymalin
Comparison of Endoluten (Low evidence) and Thymalin (Moderate evidence).
Epithalon vs Humanin
Comparison of Epithalon (Low evidence) and Humanin (Moderate evidence).
Epithalon vs Livagen
Comparison of Epithalon (Low evidence) and Livagen (Low evidence).
Epithalon vs MOTS-c
Epithalon has telomere findings in cultured cells; MOTS-c has human endogenous-peptide observations and a native Phase 2 trial registration without cited outcomes. Neither has demonstrated human longevity benefit.
Epithalon vs Ovagen
Comparison of Epithalon (Low evidence) and Ovagen (Low evidence).
Epithalon vs Pancragen
Comparison of Epithalon (Low evidence) and Pancragen (Low evidence).
Epithalon vs Pinealon
Comparing two Russian bioregulator peptides: epithalon (telomerase-focused longevity) versus pinealon (neuroprotection-focused cognitive support).
Epithalon vs Prostatilen
Comparison of Epithalon (Low evidence) and Prostatilen (Moderate evidence).
Epithalon vs Retinalamin
Comparison of Epithalon (Low evidence) and Retinalamin (Moderate evidence).
Epithalon vs Sigumir
Comparison of Epithalon (Low evidence) and Sigumir (Low evidence).
Epithalon vs Stamakort
Comparison of Epithalon (Low evidence) and Stamakort (Very Low evidence).
Epithalon vs Suprefort
Comparison of Epithalon (Low evidence) and Suprefort (Very Low evidence).
Epithalon vs Svetinorm
Comparison of Epithalon (Low evidence) and Svetinorm (Very Low evidence).
Epithalon vs Testagen
Epithalon and Testagen research, with Testagen preparation and clinical-evidence limits.
Epithalon vs Thymalin
Comparing two Russian bioregulator peptides: epithalon (telomerase/longevity focus) versus thymalin (immune restoration focus) for geroprotective applications.
Epithalon vs Ventfort
Comparison of Epithalon (Low evidence) and Ventfort (Very Low evidence).
Epithalon vs Vesugen
Comparison of Epithalon (Low evidence) and Vesugen (Low evidence).
Epithalon vs Vilon
Epithalon and Vilon research, with limited Vilon human reports and unresolved clinical questions.
Follistatin vs IGF-1 LR3
Follistatin is a human activin-binding protein, while IGF-1 LR3 is an engineered IGF-1 analogue. Their human evidence is not interchangeable with studies of follistatin gene transfer, ACE-083, or recombinant human IGF-1.
FOXO4-DRI vs Epithalon
FOXO4-DRI has senescent-cell and organ findings in experimental models; Epithalon has telomere-related findings in cultured cells. Neither set of findings establishes a human longevity benefit or clinical safety.
FOXO4-DRI vs SHLP-6
FOXO4-DRI has senescent-cell and mouse-model studies. A SHLP-6 experiment found increased apoptosis in two cell lines but did not test senescent-cell clearance. Human longevity benefits are unestablished for both.
GHK vs GHK-Cu
Comparing the tripeptide GHK with its copper-bound form GHK-Cu - understanding the importance of copper binding.
GHK-Cu vs BPC-157
Comparison of topically-used GHK-Cu and systemically-claimed BPC-157 for tissue repair applications.
GHRP-2 vs GHRP-6
Comparing two common growth hormone releasing peptides: GHRP-2 and GHRP-6, their mechanisms, effects, and research status.
GHRP-2 vs Hexarelin
Comparing two potent growth hormone releasing peptides - GHRP-2 and hexarelin for GH stimulation research.
GHRP-2 vs Ipamorelin
Comparing two growth hormone releasing peptides - potent GHRP-2 with selective ipamorelin.
GHRP-2 vs MK-677
GHRP-2 and MK-677 both stimulate growth hormone, but the cited studies cannot rank their clinical benefits or safety.
GHRP-6 vs Ipamorelin
Comparison of first-generation GHRP-6 and more selective ipamorelin - both unapproved GH secretagogues.
GHRP-6 vs MK-677
GHRP-6 GH-response studies and MK-677 clinical trials address different endpoints and do not establish a treatment ranking or combination benefit.
GHRP-6 vs Sermorelin
Comparison of GHRP-6 (Moderate evidence) and Sermorelin (Moderate evidence).
Glutathione vs SS-31
Comparing two approaches to cellular protection: glutathione (master antioxidant) versus SS-31 (mitochondria-targeting peptide) for oxidative stress and aging.
HCG vs HMG
Comparing two gonadotropin preparations: HCG (LH-like activity) versus HMG (FSH + LH activity) for fertility treatment and hormonal support.
Hexarelin vs GHRP-6
Comparing two potent growth hormone releasing peptides - hexarelin and GHRP-6 with their different side effect profiles.
Hexarelin vs Ipamorelin
Comparison of two growth hormone releasing peptides (GHRPs) - hexarelin with stronger GH release and broader receptor activity versus the more selective ipamorelin.
Human Chorionic Gonadotropin (hCG) vs Kisspeptin
Comparison of Human Chorionic Gonadotropin (hCG) (High evidence) and Kisspeptin (Moderate evidence).
Humanin vs SHLP-6
Comparison of Humanin (Moderate evidence) and SHLP-6 (Low evidence).
KPV vs BPC-157
Comparison of anti-inflammatory tripeptide KPV derived from alpha-MSH with body protection compound BPC-157 for healing and inflammatory conditions.
KPV vs Thymosin Alpha-1
Comparison of KPV (Low evidence) and Thymosin Alpha-1 (Moderate evidence).
Kristagen vs Thymalin
Comparison of Kristagen (Low evidence) and Thymalin (Moderate evidence).
Kristagen vs Thymosin Alpha-1
Comparison of Kristagen (Low evidence) and Thymosin Alpha-1 (Moderate evidence).
Kristagen vs Vilon
Kristagen and Vilon research, with limited Vilon human reports and unresolved clinical questions.
Liraglutide vs MariTide
Comparison of Liraglutide (High evidence) and MariTide (Moderate evidence).
Liraglutide vs Mazdutide
Liraglutide and mazdutide differ in mechanism, trial maturity, and regulatory status. The cited studies do not establish a head-to-head efficacy ranking.
Liraglutide vs Orforglipron
Comparison of Liraglutide (High evidence) and Orforglipron (High evidence).
Liraglutide vs Pemvidutide
Comparison of Liraglutide (High evidence) and Pemvidutide (Moderate evidence).
Liraglutide vs Retatrutide
Comparison of Liraglutide (High evidence) and Retatrutide (High evidence).
Liraglutide vs Semaglutide
Comparing first-generation daily GLP-1 agonist liraglutide with next-generation weekly semaglutide for diabetes and weight management.
Liraglutide vs SLU-PP-332
Comparison of Liraglutide (High evidence) and SLU-PP-332 (Very Low evidence).
Liraglutide vs Survodutide
Comparison of Liraglutide (High evidence) and Survodutide (High evidence).
Liraglutide vs Tirzepatide
Comparing first-generation GLP-1 agonist liraglutide (Saxenda/Victoza) versus dual-agonist tirzepatide (Zepbound/Mounjaro) for weight loss and diabetes.
Liraglutide vs VK2735
Comparison of Liraglutide (High evidence) and VK2735 (Moderate evidence).
Livagen vs Ovagen
Comparison of Livagen (Low evidence) and Ovagen (Low evidence).
Livagen vs Svetinorm
Comparison of Livagen (Low evidence) and Svetinorm (Very Low evidence).
Livagen vs Thymalin
Comparison of Livagen (Low evidence) and Thymalin (Moderate evidence).
Livagen vs Vilon
Livagen and Vilon research, with limited Vilon human reports and unresolved clinical questions.
LL-37 vs Alpha-Defensins
LL-37 is one active human cathelicidin with mixed native topical wound-trial findings; alpha-defensins are a family with varied host-defense mechanisms, including HD6 nanonets. Mechanisms do not rank human treatments.
LL-37 vs KPV
LL-37 has limited, mixed native-peptide topical wound trial findings; KPV's cited direct evidence is from cell and animal experiments. Neither has an established general clinical benefit, and they have not been compared in a therapeutic head-to-head trial in the sources reviewed here.
LL-37 vs Lactoferricin
Native topical LL-37 has mixed human wound-trial results; lactoferricin is a lactoferrin-derived fragment with directly cited antimicrobial assays. Their formulations and evidence do not support a clinical efficacy ranking.
MariTide vs Mazdutide
MariTide and mazdutide differ in mechanism, trial maturity, and regulatory status. The cited studies do not establish a head-to-head efficacy ranking.
MariTide vs Orforglipron
Comparison of MariTide (Moderate evidence) and Orforglipron (High evidence).
MariTide vs Pemvidutide
Comparison of MariTide (Moderate evidence) and Pemvidutide (Moderate evidence).
MariTide vs Retatrutide
Comparison of MariTide (Moderate evidence) and Retatrutide (High evidence).
MariTide vs Semaglutide
Comparison of MariTide (Moderate evidence) and Semaglutide (High evidence).
MariTide vs SLU-PP-332
Comparison of MariTide (Moderate evidence) and SLU-PP-332 (Very Low evidence).
MariTide vs Survodutide
Comparison of MariTide (Moderate evidence) and Survodutide (High evidence).
Maritide vs Tirzepatide
Comparison of Amgen's long-acting investigational GLP-1/GIP dual agonist maritide with FDA-approved tirzepatide for obesity and type 2 diabetes.
MariTide vs VK2735
Comparison of MariTide (Moderate evidence) and VK2735 (Moderate evidence).
Mazdutide vs Semaglutide
Mazdutide has randomized weight and diabetes evidence concentrated in Chinese adults, plus a smaller US phase 2 weight trial; Innovent reports specified approvals in China, while no FDA approval was verified. Semaglutide has a broader clinical program and product-specific FDA approvals. The limited direct comparison reviewed here is a conference abstract in selected adults with early type 2 diabetes and obesity.
Mazdutide vs Survodutide
Mazdutide and survodutide are distinct GLP-1/glucagon dual agonists, each with published phase 3 weight trials. Their trials differ in population and estimand; Innovent reports specified mazdutide approvals in China, while no FDA approval was verified for either agent.
Mazdutide vs Tirzepatide
Mazdutide is a GLP-1/glucagon dual agonist with randomized Chinese weight and diabetes trials and a separate US phase 2 weight trial; Innovent reports specified Chinese approvals. Tirzepatide is a GLP-1/GIP dual agonist with FDA-approved Mounjaro and Zepbound products. Their separate trials do not establish a head-to-head ranking.
MK-677 vs CJC-1295
MK-677 and CJC-1295 stimulate different growth hormone pathways; hormone changes have not established comparative clinical benefit.
MK-677 vs Ipamorelin
MK-677 has older-adult body-composition trials; ipamorelin has human GH-biomarker data and a separate postoperative-ileus trial without significant efficacy findings.
MK-677 vs Sermorelin
MK-677 is an oral nonpeptide ghrelin-receptor agonist; sermorelin is an injected GHRH analog with a different regulatory history.
MOTS-c vs Humanin
MOTS-c and humanin are distinct mitochondrial peptides. Human observations measure endogenous levels, while treatment evidence remains preclinical; native MOTS-c has a Phase 2 registration without a cited outcome.
MOTS-c vs SHLP-2
MOTS-c has human endogenous-peptide observations and a native Phase 2 registration without outcomes; SHLP-2 has receptor and metabolic model findings with no established human treatment effect.
MOTS-c vs SHLP-6
MOTS-c has observational human work and a registered native intervention without cited outcomes; SHLP-6 has cell, fish and limited human observation evidence without an administered-human result.
MOTS-c vs SS-31
MOTS-c has human biomarker studies and a native Phase 2 registration without a cited result. SS-31 (elamipretide) has human trials and product-specific FDA accelerated approval for Barth syndrome, with confirmatory benefit pending.
N-Acetyl Selank Amidate vs N-Acetyl Semax Amidate
Comparison of N-Acetyl Selank Amidate (Very Low evidence) and N-Acetyl Semax Amidate (Very Low evidence).
N-Acetyl Selank Amidate vs Semax
Comparison of N-Acetyl Selank Amidate (Very Low evidence) and Semax (Moderate evidence).
N-Acetyl Semax Amidate vs Selank
Comparison of N-Acetyl Semax Amidate (Very Low evidence) and Selank (Moderate evidence).
Oral vs Injectable Semaglutide
Comparison of oral (Rybelsus) and injectable (Ozempic/Wegovy) semaglutide formulations - pharmacology, efficacy, and practical differences.
Orforglipron vs Semaglutide
Eli Lilly's oral small-molecule GLP-1 agonist versus Novo Nordisk's peptide-based semaglutide.
Orforglipron vs Tirzepatide
Comparing Eli Lilly's oral non-peptide GLP-1 agonist orforglipron with injectable dual GIP/GLP-1 agonist tirzepatide.
Ovagen vs Svetinorm
Comparison of Ovagen (Low evidence) and Svetinorm (Very Low evidence).
Ovagen vs Thymalin
Comparison of Ovagen (Low evidence) and Thymalin (Moderate evidence).
Ozempic vs Mounjaro
Brand name comparison of two leading GLP-1 medications for type 2 diabetes management.
Ozempic vs Wegovy
Comparison of two semaglutide brands - same drug, different indications and dosing for diabetes vs weight management.
P21 vs Semax
Comparison of P21 (Very Low evidence) and Semax (Moderate evidence).
Pancragen vs Suprefort
Comparison of Pancragen (Low evidence) and Suprefort (Very Low evidence).
Pancragen vs Thymalin
Comparison of Pancragen (Low evidence) and Thymalin (Moderate evidence).
Pancragen vs Vilon
Pancragen and Vilon research, with limited Vilon human reports and unresolved clinical questions.
Pasireotide vs MK-677
Pasireotide has labeled uses for selected pituitary diseases; MK-677 is an unapproved secretagogue studied in different populations.
Pemvidutide vs Semaglutide
Comparing Altimmune's dual GLP-1/glucagon agonist pemvidutide with Novo Nordisk's GLP-1 agonist semaglutide.
Pemvidutide vs Survodutide
Comparison of Pemvidutide (Moderate evidence) and Survodutide (High evidence).
Pemvidutide vs Tirzepatide
Comparison of Altimmune's dual GLP-1/glucagon agonist pemvidutide with tirzepatide's GLP-1/GIP approach for obesity and metabolic disease.
Pinealon vs Semax
Comparison of Pinealon (Low evidence) and Semax (Moderate evidence).
Prostatilen vs Thymalin
Comparison of Prostatilen (Moderate evidence) and Thymalin (Moderate evidence).
Prostatilen vs Vilon
Prostatilen and Vilon research, with limited Vilon human reports and unresolved clinical questions.
PT-141 vs Kisspeptin
Comparing two peptides affecting sexual function: PT-141 (melanocortin agonist, FDA-approved) versus kisspeptin (reproductive hormone regulator, research stage).
PT-141 vs Melanotan II
Comparison of FDA-approved PT-141 (Vyleesi) and unapproved Melanotan II - related peptides with different regulatory paths.
Retatrutide vs Semaglutide
Comparison of the investigational triple agonist retatrutide to the established GLP-1 agonist semaglutide.
Retatrutide vs Survodutide
Comparing Eli Lilly's triple agonist retatrutide with Boehringer's dual GLP-1/glucagon agonist survodutide.
Retinalamin vs Thymalin
Comparison of Retinalamin (Moderate evidence) and Thymalin (Moderate evidence).
Rybelsus vs Ozempic
Comparison of oral vs injectable semaglutide formulations for type 2 diabetes - same drug, different delivery methods.
Selank vs NA-Selank-Amidate
Comparing original Selank with its N-acetyl amidated derivative NA-Selank-Amidate for stability and bioavailability.
Selank vs Semax
Comparison of two Russian neuropeptides marketed for cognitive and anxiolytic effects - neither approved in the US or EU.
Semax vs NA-Semax-Amidate
Comparing original Semax with its N-acetyl amidated derivative NA-Semax-Amidate for stability and bioavailability.
Sermorelin vs Ipamorelin
Comparing GHRH analog sermorelin with growth hormone releasing peptide ipamorelin - two different approaches to stimulating GH release.
SHLP-2 vs Humanin
Comparing two mitochondria-derived peptides from the same mtDNA region: SHLP-2 (mitochondrial function) versus humanin (cytoprotection) for aging research.
SHLP-2 vs SHLP-6
Comparison of SHLP-2 (Low evidence) and SHLP-6 (Low evidence).
SHLP-2 vs SS-31
Comparison of SHLP-2 (Low evidence) and SS-31 (Moderate evidence).
Sigumir vs TB-500
Comparison of Sigumir (Low evidence) and TB-500 (Moderate evidence).
SS-31 vs Humanin
Comparing two mitochondria-targeting peptides: SS-31 (synthetic cardiolipin binder in clinical trials) versus humanin (endogenous cytoprotective MDP).
Stamakort vs Thymalin
Comparison of Stamakort (Very Low evidence) and Thymalin (Moderate evidence).
Suprefort vs Vilon
Suprefort and Vilon research, with limited Vilon human reports and unresolved clinical questions.
Survodutide vs Semaglutide
Comparing Boehringer Ingelheim's dual GLP-1/glucagon agonist survodutide with single-target GLP-1 agonist semaglutide.
Survodutide vs Tirzepatide
Boehringer Ingelheim's GLP-1/glucagon dual agonist versus Eli Lilly's GIP/GLP-1 dual agonist for obesity and metabolic disease.
TB-500 vs GHK-Cu
Comparing TB-500 (thymosin beta-4 fragment) and GHK-Cu (copper tripeptide) for their proposed tissue repair and healing properties.
TB-500 vs LL-37
TB-500 commonly denotes a seven-residue thymosin beta-4 fragment with no cited human treatment study; LL-37 has three native topical wound-trial populations with mixed outcomes. Parent-protein results cannot validate TB-500.
TB-500 vs Thymosin Alpha-1
Comparing TB-500 (thymosin beta-4 fragment) with thymosin alpha-1 - different thymosins with different functions.
Tesamorelin vs GHRP-6
Tesamorelin has an FDA-approved excess-abdominal-fat indication in adults with HIV; GHRP-6 human studies chiefly measure short-term hormone responses.
Tesamorelin vs Ipamorelin
Tesamorelin has FDA-reviewed VAT trials for its narrow HIV-lipodystrophy indication; ipamorelin has a separate postoperative-ileus study without established benefit for that outcome.
Tesamorelin vs MK-677
Tesamorelin's approved evidence concerns VAT in adults with HIV and lipodystrophy; MK-677 is a nonpeptide secretagogue studied for different outcomes and is not FDA approved.
Tesamorelin vs Sermorelin
Tesamorelin has a current FDA-approved excess-abdominal-fat indication in adults with HIV; historical Geref sermorelin products were discontinued for reasons other than safety or effectiveness.
Testagen vs Thymalin
Testagen and Thymalin research, with Testagen preparation and clinical-evidence limits.
Testagen vs Vilon
Testagen and Vilon research, with limited Vilon human reports and unresolved clinical questions.
Thymalin vs Thymogen
Comparing two Russian thymic peptides: thymalin (calf thymus extract complex) versus thymogen (synthetic dipeptide derivative) for immunomodulation.
Thymalin vs Vilon
Thymalin and Vilon research, with limited Vilon human reports and unresolved clinical questions.
Thymalin vs Vladonix
Comparison of Thymalin (Moderate evidence) and Vladonix (Low evidence).
Thymogen vs Thymosin Alpha-1
Comparison of Thymogen (Moderate evidence) and Thymosin Alpha-1 (Moderate evidence).
Thymogen vs Thymulin
Comparison of Thymogen (Moderate evidence) and Thymulin (Moderate evidence).
Thymogen vs Vilon
Thymogen and Vilon research, with limited Vilon human reports and unresolved clinical questions.
Thymogen vs Vladonix
Comparison of Thymogen (Moderate evidence) and Vladonix (Low evidence).
Thymosin Alpha-1 vs LL-37
Thymosin alpha-1 has condition-specific human immunomodulatory trials and non-US approvals; LL-37 has mixed native topical wound-trial outcomes. Their different indications do not support a general immune-benefit ranking.
Thymosin Alpha-1 vs Thymalin
Comparing Western-developed thymosin alpha-1 (approved in 35+ countries) versus Russian thymalin (thymic extract) for immunomodulation.
Thymosin Alpha-1 vs Thymulin
Comparing two thymic peptides: thymosin alpha-1 (approved immunomodulator) versus thymulin (zinc-dependent thymic hormone) for immune function.
Thymosin Alpha-1 vs Vilon
Thymosin Alpha-1 and Vilon research, with limited Vilon human reports and unresolved clinical questions.
Thymosin Alpha-1 vs Vladonix
Comparison of Thymosin Alpha-1 (Moderate evidence) and Vladonix (Low evidence).
Thymulin vs Thymalin
Comparing two similarly-named but different thymic peptides: thymulin (French FTS nonapeptide) versus thymalin (Russian polypeptide extract).
Tirzepatide vs Retatrutide
Comparing dual-agonist tirzepatide (FDA-approved) versus triple-agonist retatrutide (Phase 3) for weight loss and metabolic disease.
Tirzepatide vs Semaglutide
An evidence-based comparison of two leading GLP-1 receptor agonists, examining mechanism, efficacy, and safety data from clinical trials.
Ventfort vs Vesugen
Comparison of Ventfort (Very Low evidence) and Vesugen (Low evidence).
Vesugen vs Vilon
Vesugen and Vilon research, with limited Vilon human reports and unresolved clinical questions.
Vilon vs Vladonix
Vilon and Vladonix research, with limited Vilon human reports and unresolved clinical questions.
VK2735 vs Semaglutide
Comparing Viking Therapeutics' dual GLP-1/GIP agonist VK2735 with Novo Nordisk's GLP-1 agonist semaglutide.
VK2735 vs Tirzepatide
Comparison of Viking Therapeutics' investigational dual GLP-1/GIP agonist VK2735 with FDA-approved tirzepatide for obesity treatment.
Wegovy vs Zepbound
Brand name comparison of the two FDA-approved GLP-1-based medications specifically indicated for chronic weight management.